U.S. - Medicaments Containing Insulin But Not Antibiotics - Market Analysis, Forecast, Size, Trends And Insights
Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.
View PricingMedicaments Containing Insulin Prices in the United States
U.S. Medicaments Containing Insulin Export Price per Ton in August 2022
In August 2022, the medicaments containing insulin price per ton stood at $123.9K (FOB, US), growing by 344% against the previous month. In general, the export price recorded modest growth. Over the period under review, the average export prices hit record highs at $232.9K per ton in June 2022; however, from July 2022 to August 2022, the export prices remained at a lower figure.
As there is only one major export destination, the average price level is determined by prices for Denmark.
From January 2022 to August 2022, the rate of growth in terms of prices for Denmark amounted to -0.8% per month.
U.S. Medicaments Containing Insulin Exports
In August 2022, approximately 5.2 tons of medicaments containing insulin but not antibiotics were exported from the United States; with a decrease of -87.3% against the previous month's figure. In general, exports recorded a perceptible curtailment. The most prominent rate of growth was recorded in July 2022 when exports increased by 13,930% month-to-month.
In value terms, medicaments containing insulin exports dropped markedly to $648K (IndexBox estimates) in August 2022. Overall, exports showed a slight descent. The most prominent rate of growth was recorded in July 2022 when exports increased by 1,580% against the previous month.
U.S. Medicaments Containing Insulin Exports by Country
Denmark (5.2 tons) was the main destination for medicaments containing insulin exports from the United States, accounting for a approximately 99% share of total exports.
From January 2022 to August 2022, the average monthly growth rate of volume to Denmark amounted to -2.9%.
In value terms, Denmark ($535K) also remains the key foreign market for medicaments containing insulin exports from the United States.
From January 2022 to August 2022, the average monthly growth rate of value to Denmark totaled -3.7%.
This report provides an in-depth analysis of the medicaments containing insulin market in the U.S.. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2030.
Product coverage:
- Prodcom 21201230 - Medicaments containing insulin but not antibiotics, for therapeutic or prophylactic uses, not put up in measured doses or for retail sale
Country coverage:
- United States
Data coverage:
- Market volume and value
- Per Capita consumption
- Forecast of the market dynamics in the medium term
- Trade (exports and imports) in the U.S.
- Export and import prices
- Market trends, drivers and restraints
- Key market players and their profiles
Reasons to buy this report:
- Take advantage of the latest data
- Find deeper insights into current market developments
- Discover vital success factors affecting the market
This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.
In this report, you can find information that helps you to make informed decisions on the following issues:
- How to diversify your business and benefit from new market opportunities
- How to load your idle production capacity
- How to boost your sales on overseas markets
- How to increase your profit margins
- How to make your supply chain more sustainable
- How to reduce your production and supply chain costs
- How to outsource production to other countries
- How to prepare your business for global expansion
While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.
-
1. INTRODUCTION
Making Data-Driven Decisions to Grow Your Business
- REPORT DESCRIPTION
- RESEARCH METHODOLOGY AND AI PLATFORM
- DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
- GLOSSARY AND SPECIFIC TERMS
-
2. EXECUTIVE SUMMARY
A Quick Overview of Market Performance
- KEY FINDINGS
- MARKET TRENDS This Chapter is Available Only for the Professional Edition PRO
-
3. MARKET OVERVIEW
Understanding the Current State of The Market and Its Prospects
- MARKET SIZE
- MARKET STRUCTURE
- TRADE BALANCE
- PER CAPITA CONSUMPTION
- MARKET FORECAST TO 2030
-
4. MOST PROMISING PRODUCT
Finding New Products to Diversify Your Business
This Chapter is Available Only for the Professional Edition PRO- TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
- BEST-SELLING PRODUCTS
- MOST CONSUMED PRODUCT
- MOST TRADED PRODUCT
- MOST PROFITABLE PRODUCT FOR EXPORT
-
5. MOST PROMISING SUPPLYING COUNTRIES
Choosing the Best Countries to Establish Your Sustainable Supply Chain
This Chapter is Available Only for the Professional Edition PRO- TOP COUNTRIES TO SOURCE YOUR PRODUCT
- TOP PRODUCING COUNTRIES
- TOP EXPORTING COUNTRIES
- LOW-COST EXPORTING COUNTRIES
-
6. MOST PROMISING OVERSEAS MARKETS
Choosing the Best Countries to Boost Your Exports
This Chapter is Available Only for the Professional Edition PRO- TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
- TOP CONSUMING MARKETS
- UNSATURATED MARKETS
- TOP IMPORTING MARKETS
- MOST PROFITABLE MARKETS
7. PRODUCTION
The Latest Trends and Insights into The Industry
- PRODUCTION VOLUME AND VALUE
8. IMPORTS
The Largest Import Supplying Countries
- IMPORTS FROM 2012–2024
- IMPORTS BY COUNTRY
- IMPORT PRICES BY COUNTRY
9. EXPORTS
The Largest Destinations for Exports
- EXPORTS FROM 2012–2024
- EXPORTS BY COUNTRY
- EXPORT PRICES BY COUNTRY
-
10. PROFILES OF MAJOR PRODUCERS
The Largest Producers on The Market and Their Profiles
This Chapter is Available Only for the Professional Edition PRO -
LIST OF TABLES
- Key Findings In 2024
- Market Volume, In Physical Terms, 2012–2024
- Market Value, 2012–2024
- Per Capita Consumption In 2012-2024
- Imports, In Physical Terms, By Country, 2012–2024
- Imports, In Value Terms, By Country, 2012–2024
- Import Prices, By Country Of Origin, 2012–2024
- Exports, In Physical Terms, By Country, 2012–2024
- Exports, In Value Terms, By Country, 2012–2024
- Export Prices, By Country Of Destination, 2012–2024
-
LIST OF FIGURES
- Market Volume, In Physical Terms, 2012–2024
- Market Value, 2012–2024
- Market Structure – Domestic Supply vs. Imports, In Physical Terms, 2012-2024
- Market Structure – Domestic Supply vs. Imports, In Value Terms, 2012-2024
- Trade Balance, In Physical Terms, 2012-2024
- Trade Balance, In Value Terms, 2012-2024
- Per Capita Consumption, 2012-2024
- Market Volume Forecast to 2030
- Market Value Forecast to 2030
- Products: Market Size And Growth, By Type
- Products: Average Per Capita Consumption, By Type
- Products: Exports And Growth, By Type
- Products: Export Prices And Growth, By Type
- Production Volume And Growth
- Exports And Growth
- Export Prices And Growth
- Market Size And Growth
- Per Capita Consumption
- Imports And Growth
- Import Prices
- Production, In Physical Terms, 2012–2024
- Production, In Value Terms, 2012–2024
- Imports, In Physical Terms, 2012–2024
- Imports, In Value Terms, 2012–2024
- Imports, In Physical Terms, By Country, 2024
- Imports, In Physical Terms, By Country, 2012–2024
- Imports, In Value Terms, By Country, 2012–2024
- Import Prices, By Country Of Origin, 2012–2024
- Exports, In Physical Terms, 2012–2024
- Exports, In Value Terms, 2012–2024
- Exports, In Physical Terms, By Country, 2024
- Exports, In Physical Terms, By Country, 2012–2024
- Exports, In Value Terms, By Country, 2012–2024
- Export Prices, By Country Of Destination, 2012–2024
300
This report provides an in-depth analysis of the medicaments containing insulin market in the U.S..
207
This report provides an in-depth analysis of the market for other medicaments for therapeutic or prophylactic uses in the U.S..
124
This report provides an in-depth analysis of the market for medicaments of alkaloids or derivatives thereof in the U.S..
117
This report provides an in-depth analysis of the market for medicaments of other antibiotics in the U.S..
284
This report provides an in-depth analysis of the medicaments containing hormones market in the U.S..
306
This report provides an in-depth analysis of the medicaments containing penicillin market in the U.S..
358
This report provides an in-depth analysis of the global medicaments containing insulin market.
222
This report provides an in-depth analysis of the global market for other medicaments for therapeutic or prophylactic uses.
297
This report provides an in-depth analysis of the global market for medicaments of alkaloids or derivatives thereof.
175
This report provides an in-depth analysis of the global market for medicaments of other antibiotics.
60
Eli Lilly reports strong Q4 2024 earnings, boosts 2025 guidance; driven by impressive GLP-1 drug sales, it remains an attractive investment opportunity.
221
Pharmaceutical companies are fiercely competing in the obesity drug market, with Eli Lilly and Novo Nordisk among the major players. Innovations and collaborations are key in this dynamic and lucrative sector.
168
Novo Holdings finalizes $16.5 billion acquisition of Catalent, enhancing pharmaceutical capabilities amidst regulatory clearance.
260
Explore the top 10 import markets for non-antibiotic, non-hormone, non-alkaloid medicaments based on the latest data. Discover the key countries driving the demand for therapeutic and prophylactic medicaments.
180
Discover the top countries by import value of non-penicillin or streptomycin antibiotic medicaments in 2023. Explore key statistics and market insights.
119
Discover the top import markets for medicaments containing hormones, including Belgium, Denmark, United States, and more. Learn about the key players in the global market for hormone medications.
60
Eli Lilly reports strong Q4 2024 earnings, boosts 2025 guidance; driven by impressive GLP-1 drug sales, it remains an attractive investment opportunity.
221
Pharmaceutical companies are fiercely competing in the obesity drug market, with Eli Lilly and Novo Nordisk among the major players. Innovations and collaborations are key in this dynamic and lucrative sector.
168
Novo Holdings finalizes $16.5 billion acquisition of Catalent, enhancing pharmaceutical capabilities amidst regulatory clearance.
260
Explore the top 10 import markets for non-antibiotic, non-hormone, non-alkaloid medicaments based on the latest data. Discover the key countries driving the demand for therapeutic and prophylactic medicaments.
